iSpecimen

iSpecimen, Inc. operates as healthcare organization that engages in procurement of human biospecimens. It collects biofluids, human tissue, hematopoietic stem, and immune cells. The company was founded by Christopher Ianelli in July 2009 and is headquartered in Lexington, MA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

iSpecimen reports improved Q1 performance, eyes growth opportunities ahead

iSpecimen's Q1 2024 earnings call highlighted improved financial performance through cost management and sales growth initiatives.
While facing challenges of lower specimen counts, the company showcased strengths in pricing power, supply efficiency, and cash position.
Opportunities lie in leveraging successful programs, exploring new markets, investing in technology, and strategic partnerships for future growth.
Overall, iSpecimen's positive outlook on operational advancements signals a commitment to sustainable growth and innovation in the healthcare sector.

iSpecimen beats revenue targets, strengthens operations for future growth

iSpecimen delivered strong Q2 2024 results, surpassing revenue targets and improving operational efficiency. The company's strategic initiatives to reduce costs, optimize workforce, and enhance supplier relationships are driving growth. While challenges like funding needs persist, iSpecimen is well-positioned for future opportunities in the healthcare specimen sector.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

iSpecimen, Inc. is a healthcare organization that engages in procurement of human biospecimen. It collects biofluids, human tissue, hematopoietic stem, and immune cells. The company was founded by Christopher Ianelli in 2009 and is headquartered in Woburn, MA.

Biospecimen Market To Exceed $13.5 Billion USD By 2032 Woburn, Massachusetts--(Newsfile Corp. - November 8, 2024) - iSpecimen Inc. (NASDAQ: ISPC) ("iSpecimen" or the "Company"), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, announced today the addressable Biospecimen contract research services market is attractive and growing. In fact, according to AceInsight Analytic, the market is presently valued at USD 4.4 billion as of 2023 and is predicted to reach USD 13.5 billion by the year 2032, growing at a 13.3% CAGR during the forecast period.

iSpecimen Named Top Competitor in $4.4 Billion USD Market

WOBURN, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, announced today a significant enhancement to its searchable inventory that provides researchers with increased access to a wide array of biospecimens vital to advancing oncology research and treatments.

iSpecimen Releases Cancer Biospecimen Offering; Orders Anticipated of Over $9,500,000 Annually

WOBURN, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, announced today the closing of its previously announced public offering of approximately $5 million of the Company's common stock and pre-funded warrants to purchase shares of common stock at a public offering price of $3.00 per share (minus $0.0001 per pre-funded warrant). The Company intends to use the proceeds of the offering for repayment of outstanding debt, potential acquisitions of assets or investments in businesses, products and technologies and for marketing and advertising services. The remainder of the proceeds will be used for working capital purposes.

iSpecimen Inc. Announces Closing of $5 Million Public Offering of Common Stock and Pre-Funded Warrants

WOBURN, Mass., Oct. 30, 2024 (GLOBE NEWSWIRE) -- iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, announced today the pricing of its public offering of approximately $5 million of the Company's common stock, and/or pre-funded warrants to purchase shares of common stock at a public offering price of $3.00 per share (minus $0.0001 per pre-funded warrant). The Company intends to use the proceeds of the offering for repayment of outstanding debt, potential acquisitions of assets or investments in businesses, products and technologies and for marketing and advertising services. The remainder of proceeds will be used for working capital purposes.

iSpecimen Inc. Announces Pricing of $5 Million Public Offering of Common Stock and Pre-Funded Warrants

WOBURN, Mass., Sept. 26, 2024 (GLOBE NEWSWIRE) -- iSpecimen Inc.  (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, announced today that it has secured a $1 million loan agreement and subsequently appointed three new members to its Board of Directors.

iSpecimen Secures $1 Million Loan; Appoints Three New Board Members

WOBURN, Mass., Sept. 11, 2024 (GLOBE NEWSWIRE) -- iSpecimen Inc.  (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers,  announced today that it will effect a reverse stock split of its issued and outstanding shares of common stock, par value $0.0001 per share, as well as any shares of common stock held by the Company in treasury, at a ratio of 1-for-20. The reverse stock split will become effective at 4:30 p.m. Eastern Time on September 13, 2024, and the Company's common stock will begin trading on a split-adjusted basis when the market opens on September 16, 2024. The Company's common stock will continue to trade on the Nasdaq Capital Market (“Nasdaq”) under the symbol "ISPC." The new CUSIP number for the Company's common stock following the reverse stock split will be 45032V207.

iSpecimen Announces 1-for-20 Reverse Stock Split

iSpecimen Inc. (NASDAQ:ISPC ) Q2 2024 Earnings Conference Call August 6, 2024 8:30 AM ET Company Participants Phil Carlson - IR, KCSA Strategic Communications Tracy Curley - CEO and CFO Leslie Hoyt - VP, Operations Conference Call Participants Matt Hewitt - Craig-Hallum Capital Group Operator Good morning everyone and welcome to the iSpecimen Second Quarter 2024 Earnings Conference Call. At this time, participants are in a listen-only mode.

iSpecimen Inc. (ISPC) Q2 2024 Earnings Call Transcript

Revenue increased 76% year-over-year to approximately $2.86 million Brielan Smiechowski Named SVP of Sales and Business Development LEXINGTON, Mass., Aug. 06, 2024 (GLOBE NEWSWIRE) -- iSpecimen Inc.  (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, today reported its financial and operating results for the three and six month periods ended June 30, 2024.

iSpecimen Reports Second Quarter 2024 Results

iSpecimen Inc. (NASDAQ:ISPC ) Q1 2024 Earnings Conference Call May 7, 2024 8:30 AM ET Company Participants Phil Carlson - Investor Relations, KCSA Strategic Communications Tracy Curley - Chief Executive Officer & Chief Financial Officer Leslie Hoyt - Senior Vice President of Operations Conference Call Participants Matt Hewitt - Craig Hallum Capital Operator Good day everyone and welcome to iSpecimen's First Quarter 2024 Results Conference Call. [Operator Instructions] This conference call is being recorded.

iSpecimen Inc. (ISPC) Q1 2024 Earnings Call Transcript

LEXINGTON, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- iSpecimen Inc.  (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, today reported its financial and operating results for the three-month period ended March 31, 2024.

iSpecimen Reports First Quarter 2024 Results

LEXINGTON, Mass., April 25, 2024 (GLOBE NEWSWIRE) -- iSpecimen Inc.  (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, today announced that it will report its financial results for the first quarter of 2024 ended March 31, 2024 before the market opens on Tuesday, May 7, 2024.

iSpecimen to Report First Quarter 2024 Financial Results on May 7, 2024

iSpecimen Inc. (ISPC) Q4 2023 Earnings Call Transcript

LEXINGTON, Mass., March 14, 2024 (GLOBE NEWSWIRE) -- iSpecimen Inc.  (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, today reported its financial and operating results for the twelve-month period ended December 31, 2023.

iSpecimen Reports Full Year 2023 Results

The Company will now report results after the market closes on March 13, 2024 and reschedules conference call to Thursday, March 14, 2024 at 8:30am Eastern The Company will now report results after the market closes on March 13, 2024 and reschedules conference call to Thursday, March 14, 2024 at 8:30am Eastern

iSpecimen Reschedules Full Year 2023 Earnings Release and Conference Call

LEXINGTON, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- iSpecimen Inc.  (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, today announced that it will report its financial results for the full year ended December 31, 2023 before the market opens on Wednesday, March 13, 2024.

iSpecimen to Report Full Year 2023 Financial Results on March 13, 2024

Partnership Aims to Optimize Quality Control and Assurance Through Digital AI Histopathology Services Partnership Aims to Optimize Quality Control and Assurance Through Digital AI Histopathology Services

iSpecimen and TriMetis Life Sciences Announce Strategic Partnership to Help Transform Tissue-Based Research

LEXINGTON, Mass., Jan. 18, 2024 (GLOBE NEWSWIRE) -- iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, announced today that it will be participating in the Maxim Group Virtual Healthcare IT Conference on January 25, 2024. Tracy Curley, Chief Executive Officer, will present at 10:00 a.m. ET.

iSpecimen to Participate in Maxim Group Healthcare IT Virtual Conference, January 24 & 25, 2024

Adds New Suppliers and Expands Existing Relationships to Provide Researchers Increased Access to Highly-Sought-After Biospecimens to Advance Oncology Research Adds New Suppliers and Expands Existing Relationships to Provide Researchers Increased Access to Highly-Sought-After Biospecimens to Advance Oncology Research

iSpecimen Strengthens Global Oncology Biospecimen Offering

iSpecimen Inc. (NASDAQ:ISPC ) Q3 2023 Earnings Conference Call November 2, 2023 8:30 AM ET Company Participants Phil Carlson - Investor Relations, KCSA Strategic Communications Tracy Curley - Chief Executive Officer and Chief Financial Officer Benjamin Bielak - Chief Information Officer Eric Langlois - Chief Revenue Officer Carly Lejnieks - Vice President of Marketing. Conference Call Participants Matt Hewitt - Craig Hallum Operator Good day, everyone, and welcome to iSpecimens Third Quarter 2020 Results Conference Call.

iSpecimen Inc. (ISPC) Q3 2023 Earnings Call Transcript

Sequential Quarterly Revenue Growth of 75% Driven by Enhanced Operational Efficiencies of iSpecimen Marketplace and Rollout of New Business Initiatives Sequential Quarterly Revenue Growth of 75% Driven by Enhanced Operational Efficiencies of iSpecimen Marketplace and Rollout of New Business Initiatives

iSpecimen Reports Third Quarter 2023 Financial and Operating Results

New Providers Facilitate Access to Diverse and Hard-to-Reach Populations and Support Complex Custom Projects New Providers Facilitate Access to Diverse and Hard-to-Reach Populations and Support Complex Custom Projects

iSpecimen Expands Proprietary Provider Network to Help Advance Infectious Disease Research

Management to Host Third Quarter 2023 Conference Call on Thursday, November 2, 2023 Management to Host Third Quarter 2023 Conference Call on Thursday, November 2, 2023

iSpecimen Preannounces Third Quarter 2023 Revenue Increase of 60-70% Sequentially

Accurate Pricing Delivered Within 24 Hours to Enhance the Customer Journey and Accelerate Medical Research Accurate Pricing Delivered Within 24 Hours to Enhance the Customer Journey and Accelerate Medical Research

iSpecimen Launches Next-Day Quote Service for Medical Researchers and Biospecimen Providers

Additional Providers Increase Biospecimen Access for Researchers Focused on Cervical, Uterine and Breast Cancers, as well as Reproductive Health, Cardiovascular Disease, Autoimmune Disorders and STIs Additional Providers Increase Biospecimen Access for Researchers Focused on Cervical, Uterine and Breast Cancers, as well as Reproductive Health, Cardiovascular Disease, Autoimmune Disorders and STIs

iSpecimen Expands Provider Network to Enhance Support for Women's Health Research

Company to Focus on Core Revenue Drivers, New Revenue Growth Opportunities from Recently Launched Sequencing Procurement Program and Expense Reductions Company to Focus on Core Revenue Drivers, New Revenue Growth Opportunities from Recently Launched Sequencing Procurement Program and Expense Reductions

News for iSpecimen Stock (ISPC)